What is Excelsior Sciences?
Excelsior Sciences is at the forefront of transforming small molecule innovation by developing chemistry that is both machine-performable and AI-usable. The company's proprietary 'smart bloccs' are automated, synthesis-ready, and AI-readable building blocks that constitute a modular chemical language. This innovative approach significantly accelerates both the discovery and manufacturing processes for new chemical entities. With a demonstrated expertise in automated synthesis and artificial intelligence, Excelsior Sciences is poised to deliver safer, more effective, and sustainable chemical solutions to the market.
How much funding has Excelsior Sciences raised?
Excelsior Sciences has raised a total of $70M across 1 funding round:
Series A
$70M
Series A (2025): $70M with participation from Khosla Ventures, Sofinnova Partners, and Deerfield
Key Investors in Excelsior Sciences
Khosla Ventures
Khosla Ventures is a venture capital firm founded in 2004, known for investing in breakthrough technologies across various sectors including AI, enterprise, and sustainable energy. They provide venture assistance and strategic advice to entrepreneurs.
Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm focused on life sciences, with expertise in healthcare and sustainability. They act as a hands-on company builder from seed to later-stage investments.
Deerfield
Deerfield Management is an investment firm dedicated to advancing healthcare through investment, intelligence, and philanthropy. They support companies across the healthcare ecosystem with flexible funding and leverage AI and data for innovation.
What's next for Excelsior Sciences?
The substantial enterprise-level backing positions Excelsior Sciences for a period of accelerated growth and market expansion. This strategic investment will likely fuel further research and development into their AI-readable building block technology, enhancing their capabilities in automated synthesis and AI-driven discovery. The company is expected to leverage this capital to scale its operations, potentially broadening its reach in the pharmaceutical and chemical manufacturing sectors, and solidifying its role as a leader in sustainable and efficient molecular innovation.
See full Excelsior Sciences company page
